Neuropsychiatric	neuropsychiatric	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
mefloquine	mefloquine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

This	this	O	O	O	O
study	study	O	O	O	O
describes	describes	O	O	O	O
neuropsychiatric	neuropsychiatric	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
after	after	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
mefloquine	mefloquine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Reactions	reactions	O	O	O	O
consisted	consisted	O	O	O	O
mainly	mainly	O	O	O	O
of	of	O	O	O	O
seizures	seizures	O	DISEASE	OTHERS	I
,	,	O	O	O	O
acute	acute	O	O	O	O
psychoses	psychoses	O	DISEASE	OTHERS	I
,	,	O	O	O	O
anxiety	anxiety	O	DISEASE	OTHERS	I
neurosis	neurosis	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
major	major	O	O	O	O
disturbances	disturbances	O	O	O	O
of	of	O	O	O	O
sleep-wake	sleep-wake	O	O	O	O
rhythm	rhythm	O	O	O	O
.	.	O	O	O	O

Side	side	O	O	O	O
effects	effects	O	O	O	O
occurred	occurred	O	O	O	O
after	after	O	O	O	O
both	both	O	O	O	O
therapeutic	therapeutic	O	O	O	O
and	and	O	O	O	O
prophylactic	prophylactic	O	O	O	O
intake	intake	O	O	O	O
and	and	O	O	O	O
were	were	O	O	O	O
graded	graded	O	O	O	O
from	from	O	O	O	O
moderate	moderate	O	O	O	O
to	to	O	O	O	O
severe	severe	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
a	a	O	O	O	O
risk	risk	O	O	O	O
analysis	analysis	O	O	O	O
of	of	O	O	O	O
neuropsychiatric	neuropsychiatric	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
in	in	O	O	O	O
Germany	germany	O	O	O	O
,	,	O	O	O	O
it	it	O	O	O	O
is	is	O	O	O	O
estimated	estimated	O	O	O	O
that	that	O	O	O	O
one	one	O	O	O	O
of	of	O	O	O	O
8,000	8,000	O	O	O	O
mefloquine	mefloquine	CHEMICALS	O	OTHERS	I
users	users	O	O	O	O
suffers	suffers	O	O	O	O
from	from	O	O	O	O
such	such	O	O	O	O
reactions	reactions	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
incidence	incidence	O	O	O	O
calculation	calculation	O	O	O	O
revealed	revealed	O	O	O	O
that	that	O	O	O	O
one	one	O	O	O	O
of	of	O	O	O	O
215	215	O	O	O	O
therapeutic	therapeutic	O	O	O	O
users	users	O	O	O	O
had	had	O	O	O	O
reactions	reactions	O	O	O	O
,	,	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
one	one	O	O	O	O
of	of	O	O	O	O
13,000	13,000	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
prophylaxis	prophylaxis	O	O	O	O
group	group	O	O	O	O
,	,	O	O	O	O
making	making	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
neuropsychiatric	neuropsychiatric	O	O	O	O
reactions	reactions	O	O	O	O
after	after	O	O	O	O
mefloquine	mefloquine	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
60	60	O	O	O	O
times	times	O	O	O	O
higher	higher	O	O	O	O
than	than	O	O	O	O
after	after	O	O	O	O
prophylaxis	prophylaxis	O	O	O	O
.	.	O	O	O	O

Therefore	therefore	O	O	O	O
,	,	O	O	O	O
certain	certain	O	O	O	O
limitations	limitations	O	O	O	O
for	for	O	O	O	O
malaria	malaria	O	O	OTHERS	I
prophylaxis	prophylaxis	O	O	O	O
and	and	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
mefloquine	mefloquine	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
recommended	recommended	O	O	O	O
.	.	O	O	O	O

